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To determine whether the incidence of canine leishma-
niasis has increased on Crete, Greece, we fitted infection 
models to serodiagnostic records of 8,848 dog samples for 
1990–2006. Models predicted that seroprevalence has in-
creased 2.4% (95% confidence interval 1.61%–3.51%) per 
year and that incidence has increased 2.2- to 3.8-fold over 
this 17-year period.
Zoonotic visceral leishmaniasis (ZVL) caused by Leish-mania infantum is a disease of humans and domestic 
dogs (the reservoir) transmitted by phlebotomine sandflies. 
According to the World Health Organization (1), ZVL 
was first recorded on Crete in 1907, after which it fea-
tured prominently in medical literature as a serious public 
health problem. In Chania, Crete, the annual incidence in 
the 1930s was 50 cases/30,000 population (2), and 21% of 
1,115 dogs were positive for ZVL by the formol-gel sero-
logic test; 30% of those were symptomatic (1). 
After World War II, use of DDT against malaria vec-
tors and focal destruction of Leishmania spp.–infected 
dogs is thought to have reduced ZVL on Crete (3). Sand-
flies were not found in villages systematically sprayed dur-
ing 1946–1949 compared with unsprayed villages (4). Dur-
ing 1951–1975, only 33 alleged human ZVL cases were 
recorded on Crete (5), and reports of canine ZVL were 
scanty. In 1983 a serosurvey of 72 stray dogs in Chania 
identified only 1 infected dog (1).
By the late 1980s, Phlebotomus neglectus, the putative 
vector of L. infantum on Crete (6), was abundant in stone 
walls inside and outside villages around Heraklion (7). 
During 1999–2004, P. neglectus was found in abundance 
in human dwellings and rural locations (hollows in olive 
trees and near rodent burrows) (8). Since 1991, 38 persons 
who came to hospitals in Heraklion were confirmed as hav-
ing cases of ZVL. Today, canine infection is confirmed 
throughout the island (M. Antoniou, unpub. data), and se-
roprevalences (30%–40%) are some of the highest reported 
in Europe. These accounts anecdotally suggest that the 
incidence of ZVL has increased on Crete during the past 
decade, which, if so, would be relevant to the public and 
veterinary health sectors.
The Study
We statistically examined diagnostic records of 8,848 
dogs sampled in the eastern Crete districts of Lasithi and 
Heraklion during 1990–2006. Data were supplied by the 
Faculty of Medicine, University of Crete (n = 1,205 dogs 
from 97 villages tested by using an indirect immuno-
fluorescent antibody test [IFAT], cutoff titer 160, during 
1999–2006, accompanied by demographic and geograph-
ic records); and by the Ministry of Agriculture Serology 
Laboratory, Heraklion (n = 7,643 dogs tested by using an 
IFAT, cutoff titer 200, during 1999–2005, but without ac-
companying records). Samples were collected by veterinar-
ians in private practice from any dog initially brought to 
their clinic for any reason, or by government veterinarians 
for any dog encountered, irrespective of clinical condition, 
during prearranged visits to villages. Numbers of villages 
and dogs sampled in any year depended on available re-
sources at the time.
To reduce potential sampling bias, we first tested sero-
logic data from 6 villages (located 9–45 km apart) consis-
tently sampled annually during 1999–2006 (n = 744 dogs). 
The age-adjusted annual prevalence increased significantly 
with sample year (odds ratio [OR] 1.18, 95% confidence 
interval [CI] 1.089–1.271, p<0.001) and showed no sig-
nificant differences in slope or intercept (by using robust 
standard errors) compared with data from 91 less consis-
tently sampled villages with demographic records (n = 461 
dogs; slope × village group interaction OR 0.91, 95% CI 
0.800–1.023, p not significant; intercepts OR 5.35, 95% CI 
0.902–3.688, p not significant).
These combined datasets were then compared with 
crude prevalence data for 1990–2005 (n = 7,643 dogs) cal-
culated from the ministry records; no difference was de-
tected in prevalence slopes (slope × data source interaction 
OR 1.06, 95% CI 0.995–1.30, p not significant; Figure). 
In univariable or multivariable logistic regression that con-
trolled for dog age and clustering on villages (1999–2006, n 
= 1,205 dogs), no statistical confounding of the probability 
of a dog being seropositive was attributed to dog use (com-
panion, guard, or hunting dog), sex, crude habitat type, or 
village altitude (p>0.215; see online Technical Appendix 
Table, available from www.cdc.gov/EID/content/15/6/932-
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Techapp.pdf). The final fit of seroprevalence against time 
was significant (OR 1.24, 95% CI 1.221–1.264, p<0.001), 
and the linearized difference in model prevalence (and bi-
nomial confidence limits) over the 17-year study equated 
to a mean prevalence increase of –ln(1 – 0.321)/16 = 2.4% 
(95% CI 1.61%–3.51%) per year.
To assess the change in infection incidence, our prin-
cipal aim, we used 3 standard epidemiologic models (9–11; 
online Technical Appendix) to calculate infection rates 
accounting for time, dog age, and potential loss of infec-
tion. The first method (model 1) used the cross-sectional 
age-prevalence data (IFAT cutoff titer 160), in which the 
proportion of seropositive dogs in each age class is fitted by 
varying the rates of infection and recovery. A second meth-
od (model 2) used these same data to describe the infection 
rate as it varied with both time and age until reaching the 
best fit. The third method (model 3) estimated the infection 
rate from longitudinal data of previously unexposed dogs 
<12 months of age that were followed up during 1 trans-
mission season.
Results from the 3 models were consistent (Tables 1, 
2) and showed a relative increase in the mean infection rate 
estimated to be 2.20–3.78-fold higher during 2005–2006 
than during 1999–2000. The models differed in approach 
and age of dogs considered by necessity of the model, num-
ber of estimated parameters, or model reduction. Inclusion 
of a parameter describing loss of infection (Table 1, model 
1) did not significantly lower the infection rate estimates as 
might be expected compared with a single parameter (Table 
1, model 2) or longitudinal (Table 2, model 3) model, both 
of which identified younger (<2 years of age) dogs to be at 
substantially greater risk for infection (p<0.0001).
Conclusions
The potential contribution of any improvements in di-
agnostic test sensitivity or vigilance to the increasing inci-
dence of ZVL infection is unclear. The difference in cutoff 
titers between data sources minimally shifted the abso-
lute prevalence values, but not relative prevalence slopes, 
with time (Figure). Any loss of infection with age (Table 
1, model 1) could result from nonmutually exclusive bio-
logic processes including recovery from infection, death, 
or reduced past exposure (9,11). The latter possibility is 
unlikely on Crete because of the higher risk identified in 
young dogs in all biannual periods. Disproportionate num-
bers of deaths of seropositive dogs is not suggested by a 
decline in ZVL clinical signs in older dogs in this study 
(data not shown) or elsewhere (11,12). Loss of detectable 
Leishmania-specific antibody is the more likely explana-
tion because the observed rates of serorecovery are not 
dissimilar to those (e.g., 0.062/month) estimated by cohort 
studies elsewhere (12).
Actual infection rates are likely to be higher than 
those shown here because IFAT sensitivity is <100%. 
Similarly, absolute prevalences, particularly low values for 
1990–1991, should be treated with caution because the of-
ficial leishmaniasis control program on Crete (1984–1995) 
began before this period when infection was presumably 
sufficient on the island to warrant intervention. The inter-
vention comprised elimination of IFAT-seropositive dogs 
(cutoff titer 400) but did not include insecticide spraying 
(DDT spraying ceased in 1950; V. Chatzistefanou, pers. 
comm.).
The continual increase in canine seroprevalence during 
the latter part of the intervention (Figure) suggests that the 
culling policy was unsuccessful in reducing transmission; 
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 Figure. Annual seroprevalence of zoonotic visceral leishmaniasis in 
dogs on Crete, Greece, 1990–2006. Shown are logistic fits of age-
adjusted prevalences (line and squares) for dogs from 97 villages 
(indirect immunofluoresecent antibody test [IFAT] cutoff titer 160) 
and crude seroprevalences (line and triangles) calculated from 
records of the Veterinary Laboratory of Heraklion, Crete, Hellenic 
Ministry of Rural Development and Food (www.minagric.gr) (IFAT 
cutoff titer 200). Binomial standard error bars are shown.
Table 1. Variation in incidence over time estimated from cross-sectional data for 1,205 dogs with accompanying demographic records, 
Crete, Greece, 1990–2006* 
Model 1 Model 2 
Period Incidence/mo 95% CI Loss of infection/mo 95% CI Incidence/mo 95% CI 
No.
dogs
1999–2000 0.016 0.0107–0.0206 0.045 0.0260–0.0645 0.015 0.0093–0.0213 237
2001–2002 0.029 0.0114–0.0455 0.071 0.0201–0.1211 0.023 0.0166–0.0298 219
2003–2004 0.030 0.0216–0.0381 0.049 0.0320–0.0667 0.029 0.0221–0.0367 401
2005–2006 0.059 0.0233–0.0946 0.106 0.0383–0.17430 0.032 0.0205–0.0477 348
*Only model 1 is designed to estimate loss of infection (serorecovery). CI, confidence interval. A full description of these models is available in the online 
Technical Appendix (available from www.cdc.gov/EID/content/15/6/932-Techapp.pdf). 
likely reasons for the low efficacy of dog culling in other 
leishmaniasis-endemic regions have been described (13). 
Officially, destruction of seropositive dogs is still required 
today unless the owner agrees to veterinary treatment of the 
dog or to keep the dog under sandfly-proof netting. How-
ever, there is no current policy on Crete to combat vectors. 
We conclude that the results of our study are consistent with 
a postwar reemergence and current increasing incidence of 
ZVL infection on Crete.
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Table 2. Variation in incidence over time estimated from 
longitudinal data for 179 dogs with accompanying demographic 
records, Crete, Greece, 1990–2006* 
Model 3 
Period
No positive/ 
no. tested 
Incidence/
mo 95% CI 
1999–2000 6/56 0.014 0.0061–0.0280 
2001–2002 7/30 0.033 0.0153–0.0612 
2003–2004 12/56 0.030 0.0172–0.0490 
2005–2006 10/37 0.039 0.0210–0.0670 
*CI, confidence interval. A full description of this model is available in the 
online Technical Appendix (available from ww.cdc.gov/EID/content/15/6/932-
Techapp.pdf). 
